Michael Kors Holdings (KORS) Tops Q3 EPS by 25c; Boosts FY14 Outlook
Get Alerts KORS Hot Sheet
Join SI Premium – FREE
Michael Kors Holdings (NYSE: KORS) reported Q3 EPS of $1.11, $0.25 better than the analyst estimate of $0.86. Revenue for the quarter came in at $1 billion versus the consensus estimate of $859.94 million.
Retail net sales increased 51.3% to $503.4 million driven by a 27.8% increase in comparable store sales and 98 net new store openings since the end of the third quarter of fiscal 2013. Wholesale net sales increased 68.2% to $461.4 million and licensing revenue increased 59.0% to $47.4 million.
Michael Kors Holdings sees Q4 2014 EPS of $0.63-$0.65, versus the consensus of $0.65. Michael Kors Holdings sees Q4 2014 revenue of $790-800 million, versus the consensus of $790.86 million.
Michael Kors Holdings sees FY2014 EPS of $3.07-$3.09, versus the consensus of $2.83. Michael Kors Holdings sees FY2014 revenue of $3.18-3.19 billion, versus the consensus of $3.03 billion.
For earnings history and earnings-related data on Michael Kors Holdings (KORS) click here.
Retail net sales increased 51.3% to $503.4 million driven by a 27.8% increase in comparable store sales and 98 net new store openings since the end of the third quarter of fiscal 2013. Wholesale net sales increased 68.2% to $461.4 million and licensing revenue increased 59.0% to $47.4 million.
Michael Kors Holdings sees Q4 2014 EPS of $0.63-$0.65, versus the consensus of $0.65. Michael Kors Holdings sees Q4 2014 revenue of $790-800 million, versus the consensus of $790.86 million.
Michael Kors Holdings sees FY2014 EPS of $3.07-$3.09, versus the consensus of $2.83. Michael Kors Holdings sees FY2014 revenue of $3.18-3.19 billion, versus the consensus of $3.03 billion.
For earnings history and earnings-related data on Michael Kors Holdings (KORS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Marchex (MCHX) Reports In-Line Q2 EPS
- Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Corp. News, Hot Guidance, Retail SalesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share